# ALX-0171 Safety Study in Adults With Hyperresponsive Airways

> **NCT01909843** · PHASE1 · COMPLETED · sponsor: **Ablynx, a Sanofi company** · enrollment: 24 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infection

## Interventions

- **BIOLOGICAL:** ALX-0171

## Key facts

- **NCT ID:** NCT01909843
- **Lead sponsor:** Ablynx, a Sanofi company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2018-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01909843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01909843, "ALX-0171 Safety Study in Adults With Hyperresponsive Airways". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01909843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*